Geron Corporation (GERN): Price and Financial Metrics


Geron Corporation (GERN): $3.05

-0.15 (-4.69%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add GERN to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

GERN POWR Grades

  • GERN scores best on the Quality dimension, with a Quality rank ahead of 34.6% of US stocks.
  • GERN's strongest trending metric is Sentiment; it's been moving down over the last 177 days.
  • GERN ranks lowest in Stability; there it ranks in the 6th percentile.

GERN Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for GERN is 0.01 -- better than merely 9.03% of US stocks.
  • GERN's price/sales ratio is 803.25; that's higher than the P/S ratio of 99.47% of US stocks.
  • Revenue growth over the past 12 months for GERON CORP comes in at 280.4%, a number that bests 96.74% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to GERON CORP, a group of peers worth examining would be PRQR, OGEN, DARE, IMGN, and IMRX.
  • GERN's SEC filings can be seen here. And to visit GERON CORP's official web site, go to www.geron.com.

GERN Valuation Summary

  • GERN's price/sales ratio is 795.8; this is 37795.24% higher than that of the median Healthcare stock.
  • Over the past 243 months, GERN's price/sales ratio has gone up 763.8.

Below are key valuation metrics over time for GERN.

Stock Date P/S P/B P/E EV/EBIT
GERN 2023-01-30 795.8 11.3 -9.3 -9.7
GERN 2023-01-27 830.6 11.8 -9.7 -10.1
GERN 2023-01-26 838.1 11.9 -9.8 -10.2
GERN 2023-01-25 845.5 12.0 -9.9 -10.3
GERN 2023-01-24 845.5 12.0 -9.9 -10.3
GERN 2023-01-23 813.2 11.5 -9.5 -9.9

GERN Growth Metrics

    Its 5 year net cashflow from operations growth rate is now at -185.03%.
  • The 4 year price growth rate now stands at -38.78%.
  • Its 3 year revenue growth rate is now at 71.3%.
GERN's revenue has moved up $1,131,000 over the prior 15 months.

The table below shows GERN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 1.533 -114.366 -131.283
2022-06-30 1.345 -107.624 -116.929
2022-03-31 1.379 -96.796 -118.386
2021-12-31 1.393 -95.556 -116.112
2021-09-30 0.403 -86.002 -107.882
2021-06-30 0.402 -78.611 -100.836

GERN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • GERN has a Quality Grade of C, ranking ahead of 52.18% of graded US stocks.
  • GERN's asset turnover comes in at 0.002 -- ranking 426th of 682 Pharmaceutical Products stocks.
  • NSTG, NEOG, and CLVS are the stocks whose asset turnover ratios are most correlated with GERN.

The table below shows GERN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.002 1 -0.424
2021-03-31 0.001 1 -0.352
2020-12-31 0.001 1 -0.350
2020-09-30 0.002 1 -0.448
2020-06-30 0.002 1 -0.503
2020-03-31 0.003 1 -0.589

GERN Price Target

For more insight on analysts targets of GERN, see our GERN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $4.20 Average Broker Recommendation 1.38 (Strong Buy)

GERN Stock Price Chart Interactive Chart >

Price chart for GERN

GERN Price/Volume Stats

Current price $3.05 52-week high $3.84
Prev. close $3.20 52-week low $1.00
Day low $3.03 Volume 4,462,541
Day high $3.18 Avg. volume 14,383,888
50-day MA $2.71 Dividend yield N/A
200-day MA $2.15 Market Cap 1.16B

Geron Corporation (GERN) Company Bio


Geron Corporation focuses on the development of telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. The company was founded in 1990 and is based in Menlo Park, California.


GERN Latest News Stream


Event/Time News Detail
Loading, please wait...

GERN Latest Social Stream


Loading social stream, please wait...

View Full GERN Social Stream

Latest GERN News From Around the Web

Below are the latest news stories about GERON CORP that investors may wish to consider to help them evaluate GERN as an investment opportunity.

10 Hot Healthcare Stocks To Buy Now

In this article, we discuss the 10 hot healthcare stocks to buy now. If you want to read about some more hot healthcare stocks to buy now, go directly to 5 Hot Healthcare Stocks To Buy Now. The rise of consumer prices has often lagged behind healthcare inflation, which includes costs for doctor visits, surgeries, […]

Yahoo | February 3, 2023

Geron (GERN) Stock Sinks As Market Gains: What You Should Know

Geron (GERN) closed the most recent trading day at $3.34, moving -1.18% from the previous trading session.

Yahoo | February 2, 2023

Is Achilles Therapeutics (ACHL) Outperforming Other Medical Stocks This Year?

Here is how Achilles Therapeutics PLC Sponsored ADR (ACHL) and Geron (GERN) have performed compared to their sector so far this year.

Yahoo | February 2, 2023

7 A-Rated Stocks to Buy for Less Than $25

So, what are the best stocks to buy for less than $25 per share?

Louis Navellier and the InvestorPlace Research Staff on InvestorPlace | January 24, 2023

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., January 19, 2023--Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 75,730 shares of Geron common stock as inducements to a newly hired employee in connection with commencement of employment with the Company.

Yahoo | January 19, 2023

Read More 'GERN' Stories Here

GERN Price Returns

1-mo 3.39%
3-mo 34.96%
6-mo 29.79%
1-year 201.98%
3-year 129.32%
5-year 35.56%
YTD 26.03%
2022 98.36%
2021 -23.27%
2020 16.91%
2019 36.00%
2018 -44.44%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9321 seconds.